Bempegaldesleukin (BEMPEG/NKTR-214)
Has anyone heard of this? Really interesting mechanism. Came across it from here.
https://ascopubs.org/doi/full/10.1200/JCO.21.00675
PURPOSE
Therapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metastatic melanoma.
METHODS
A total of 41...
Read more
Source: Student Doctor Network - Category: Universities & Medical Training Authors: fiji128 Tags: Radiation Oncology Source Type: forums
More News: Cancer & Oncology | Melanoma | Skin Cancer | Students | Study | Universities & Medical Training